Literature DB >> 31078045

Intrinsic β-catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer.

Junli Xue1, Xuetao Yu2, Liqiong Xue1, Xiaoxiao Ge1, Wei Zhao1, Wei Peng3.   

Abstract

Colorectal cancer is the third most common cancer worldwide and shows resistance to immune checkpoint inhibitors which have been demonstrated to be effective in many other types of cancers. Pre-existing T-cell response in tumor microenvironment often determines the therapeutic benefit of immune checkpoint blockade. Tumor-infiltrating CD8+ T-cells are considered as the major effector immune cells in antitumor immunity. In this study, we aimed to identify the intrinsic oncogenic pathway that contributes to a reduction of CD8+ T-cell infiltration in colorectal cancer. To achieve this, human colon adenocarcinoma samples derived from The Cancer Genome Altas (TCGA) were stratified into low T-cell-inflamed and high T-cell-inflamed groups based on the expression of T-cell signature genes. Gene set enrichment analysis of revealed a close correlation between activation of the Wnt/β-catenin signaling pathway and absence of T-cell infiltration. By immunohistochemical analysis of 155 colorectal cancer tissues, we found that tumors with high β-catenin expression showed a significant reduction of CD8+ T-cell infiltration. Mechanistically, β-catenin can regulate CCL4 expression to recruit CD103+ dendritic cells to enable CD8+ T cell activation. Collectively, our data indicate that oncogenic β-catenin signal may mediate colorectal cancer resistance to immunotherapies, pointing to the combined PD-1-immunotherapy with targeting β-catenin in colorectal cancer.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Immune checkpoint blockade; Immunotherapy; T-cell infiltration; β-catenin

Mesh:

Substances:

Year:  2019        PMID: 31078045     DOI: 10.1016/j.biopha.2019.108921

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  19 in total

1.  Turning a Targeting β-Catenin/Bcl9 Peptide Inhibitor into a GdOF@Au Core/Shell Nanoflower for Enhancing Immune Response to Cancer Therapy in Combination with Immune Checkpoint Inhibitors.

Authors:  Weiming You; Fang Ma; Zhang Zhang; Jin Yan
Journal:  Pharmaceutics       Date:  2022-06-20       Impact factor: 6.525

2.  Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma.

Authors:  Xuechao Wu; Peng Hou; Yun Qiu; Qing Wang; Xiaojie Lu
Journal:  Onco Targets Ther       Date:  2020-07-31       Impact factor: 4.147

Review 3.  Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

4.  The Role of TROP2 in BCC and Cutaneous SCC: A Clinical and Immunohistochemical Study.

Authors:  Azza Gaber Antar Farag; Hala Said El-Rebey; Mohamed Abd El-Moneim Shoeib; Shimaa Mohammed Ahmed El-Fiky; Mustafa Elsayed Elshaib; Amal Farid Mostafa
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-06-01

5.  Th17 cells inhibit CD8+ T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients.

Authors:  Dan Wang; Weina Yu; Jingyao Lian; Qian Wu; Shasha Liu; Li Yang; Feng Li; Lan Huang; Xinfeng Chen; Zhen Zhang; Aitian Li; Jinbo Liu; Zhenqiang Sun; Junxia Wang; Weitang Yuan; Yi Zhang
Journal:  J Hematol Oncol       Date:  2020-06-05       Impact factor: 17.388

6.  Immune cell infiltration as a biomarker for the diagnosis and prognosis of digestive system cancer.

Authors:  Sheng Yang; Tong Liu; Yanping Cheng; Yunfei Bai; Geyu Liang
Journal:  Cancer Sci       Date:  2019-11-02       Impact factor: 6.716

7.  PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15.

Authors:  Kyung Hwan Kim; Hong Kwan Kim; Hyung-Don Kim; Chang Gon Kim; Hoyoung Lee; Ji Won Han; Seong Jin Choi; Seongju Jeong; Minwoo Jeon; Hyunglae Kim; Jiae Koh; Bo Mi Ku; Su-Hyung Park; Myung-Ju Ahn; Eui-Cheol Shin
Journal:  Cell Mol Immunol       Date:  2020-04-24       Impact factor: 11.530

8.  Prognostic significance of CD163+ tumor-associated macrophages in colorectal cancer.

Authors:  Tao Xue; Kejing Yan; Yiqi Cai; Jiancheng Sun; Zhejing Chen; Xiaolei Chen; Wenyi Wu
Journal:  World J Surg Oncol       Date:  2021-06-24       Impact factor: 2.754

Review 9.  HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.

Authors:  Per Anderson; Natalia Aptsiauri; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Cell Mol Immunol       Date:  2021-01-20       Impact factor: 22.096

Review 10.  Targeting the immune milieu in gastrointestinal cancers.

Authors:  Fiona Turkes; Justin Mencel; Naureen Starling
Journal:  J Gastroenterol       Date:  2020-08-03       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.